vepdegestrant
Selected indexed studies
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. (N Engl J Med, 2025) [PMID:40454645]
- Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. (Clin Cancer Res, 2024) [PMID:38819400]
- VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. (Future Oncol, 2024) [PMID:39072356]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. (2025) pubmed
- Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. (2024) pubmed
- VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. (2024) pubmed
- Vepdegestrant for the treatment of HR+/HER2- breast cancer. (2025) pubmed
- PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER(+)HER2(-) breast cancer harbouring acquired ESR1 mutations. (2025) pubmed
- Vepdegestrant in Advanced Breast Cancer. (2025) pubmed
- Vepdegestrant in Advanced Breast Cancer. (2025) pubmed
- Vepdegestrant in Advanced Breast Cancer. Reply. (2025) pubmed
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders. (2025) pubmed
- Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. (2025) pubmed